Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis
暂无分享,去创建一个
[1] L. Carbonaro,et al. Focal Liver Lesions in Budd-Chiari Syndrome: Spectrum of Imaging Findings , 2023, Diagnostics.
[2] A. Gasbarrini,et al. Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications , 2023, Cells.
[3] J. Ampuero,et al. Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial , 2023, Journal of Hepatology.
[4] J. García‐Pagán,et al. Primary Budd-Chiari Syndrome. , 2023, The New England journal of medicine.
[5] C. Diaconu,et al. Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature , 2023, World journal of clinical oncology.
[6] S. Chevret,et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis. , 2023, Journal of hepatology.
[7] M. Giuffré,et al. Pylephlebitis: A Systematic Review on Etiology, Diagnosis, and Treatment of Infective Portal Vein Thrombosis , 2023, Diagnostics.
[8] Samar H. Ibrahim,et al. The evolving role of liver sinusoidal endothelial cells in liver health and disease. , 2023, Hepatology.
[9] M. Ronot,et al. Management of splanchnic vein thrombosis , 2023, JHEP reports : innovation in hepatology.
[10] A. Gasbarrini,et al. From coagulation imbalance to prediction of advanced chronic liver disease decompensation: the wind of change? , 2023, Journal of hepatology.
[11] Won-Mook Choi,et al. Porto-Sinusoidal Vascular Disease: A Concise Updated Summary of Epidemiology, Pathophysiology, Imaging, Clinical Features, and Treatments , 2023, Korean journal of radiology.
[12] Zongli Zhang,et al. Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis , 2022, Frontiers in Oncology.
[13] V. Vilgrain,et al. Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis , 2022, NEJM Evidence.
[14] A. Gasbarrini,et al. Low ADAMTS-13/VWF ratio and altered gut–liver axis predict complications of advanced chronic liver disease: a pilot study , 2022, Gastroenterology report.
[15] A. Mullally,et al. Molecular Pathogenesis of Myeloproliferative Neoplasms , 2022, Current Hematologic Malignancy Reports.
[16] Dhir Gala,et al. Thromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview , 2022, Diseases.
[17] M. Jovanović,et al. Suppurative Thrombosis of the Portal Vein (Pylephlebits): A Systematic Review of Literature , 2022, Journal of clinical medicine.
[18] E. Chouery,et al. Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study , 2022, Hepatology.
[19] F. Ponziani,et al. ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portavein thrombosis in compensated cirrhosis. A prospective observational study. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[20] C. Sempoux,et al. Porto-sinusoidal vascular disorder. , 2022, Journal of hepatology.
[21] E. Yoshida,et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. , 2022, European journal of internal medicine.
[22] Tamara Milovanovic,et al. Celiac Disease and Thrombotic Events: Systematic Review of Published Cases , 2022, Nutrients.
[23] V. de Lédinghen,et al. Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications , 2022 .
[24] H. Yoshiji,et al. ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability , 2022, Journal of clinical medicine.
[25] M. Trauner,et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. , 2022, Journal of hepatology.
[26] A. Falanga,et al. Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective , 2021, Thrombosis Update.
[27] H. Yoshiji,et al. Baveno VII - Renewing consensus in portal hypertension. , 2021, Journal of hepatology.
[28] F. Depasse,et al. Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine , 2021, Journal of thrombosis and haemostasis : JTH.
[29] R. Borrás,et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. , 2021, Journal of hepatology.
[30] M. Juan,et al. Autoimmune biomarkers in porto‐sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[31] J. Lozano,et al. Coexpression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. , 2021, Journal of hepatology.
[32] Shuang Han,et al. mTOR regulates GPVI-mediated platelet activation , 2021, Journal of Translational Medicine.
[33] L. Goldfinger,et al. Platelets and extracellular vesicles and their cross-talk with cancer. , 2021, Blood.
[34] Jian-Bo Han,et al. Predictive Value of Inflammation Biomarkers in Patients with Portal Vein Thrombosis , 2021, Journal of clinical and translational hepatology.
[35] T. Hilberg,et al. Sport and Venous Thromboembolism Site, Accompanying Features, Symptoms, and Diagnosis. , 2021, Deutsches Arzteblatt international.
[36] C. James,et al. Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms , 2021, Leukemia.
[37] R. Francés,et al. Role of liver sinusoidal endothelial cells in liver diseases , 2021, Nature Reviews Gastroenterology & Hepatology.
[38] Jing Zhang,et al. Evaluation of Coagulation, Fibrinolysis and Endothelial Biomarkers in Cirrhotic Patients With or Without Portal Venous Thrombosis , 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[39] Shi-yao Chen,et al. Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis , 2020, Canadian journal of gastroenterology & hepatology.
[40] R. Hoffman,et al. Clinical Insights into the Origins of Thrombosis in Myeloproliferative Neoplasms. , 2020, Blood.
[41] J. Crespo,et al. Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders , 2020, Journal of clinical medicine.
[42] P. D. de Groot,et al. Interplay between platelets and coagulation , 2020, Blood Reviews.
[43] Xiaoquan Huang,et al. Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis , 2020, Annals of translational medicine.
[44] F. Violi,et al. Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta‐Analysis , 2020, Hepatology communications.
[45] P. Reese,et al. Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation , 2020, Hepatology.
[46] Bao-yan Xu,et al. Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients with Cirrhosis and Acute Decompensation. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[47] J. Trebicka,et al. Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis , 2020, Clinical and translational gastroenterology.
[48] V. Patel,et al. Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay , 2020, Journal of thrombosis and haemostasis : JTH.
[49] H. You,et al. [Clinical features and risk factors of portal vein thrombosis in 28 patients with antiphospholipid syndrome]. , 2019, Zhonghua nei ke za zhi.
[50] S. Llerena,et al. Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It , 2019, Cells.
[51] T. Schiano,et al. Idiopathic noncirrhotic portal hypertension. , 2019, Seminars in diagnostic pathology.
[52] A. de Gottardi,et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. , 2019, Journal of hepatology.
[53] S. Caldwell,et al. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. , 2019, Gastroenterology.
[54] V. Vilgrain,et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. , 2019, The lancet. Gastroenterology & hepatology.
[55] M. Armstrong,et al. Review article: a multidisciplinary approach to the diagnosis and management of Budd‐Chiari syndrome , 2019, Alimentary pharmacology & therapeutics.
[56] D. Valla,et al. Nonselective beta‐blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study , 2019, Alimentary pharmacology & therapeutics.
[57] C. Mulder,et al. Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[58] Z. Sparchez,et al. Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis , 2018, The American Journal of Gastroenterology.
[59] T. Barbui,et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis , 2018, Blood Cancer Journal.
[60] C. Sempoux,et al. Histology of portal vascular changes associated with idiopathic non‐cirrhotic portal hypertension: nomenclature and definition , 2018, Histopathology.
[61] S. Sarin,et al. Budd–Chiari syndrome: a focussed and collaborative approach , 2018, Hepatology International.
[62] Han‐Chieh Lin,et al. Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats , 2018, Digestive Diseases and Sciences.
[63] C. Denis,et al. Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression , 2018, Haematologica.
[64] V. Vanneaux,et al. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features , 2018, Thrombosis and Haemostasis.
[65] P. Poredos,et al. Endothelial Dysfunction and Venous Thrombosis , 2018, Angiology.
[66] M. Ronot,et al. Diagnosis of Budd–Chiari syndrome , 2018, Abdominal Radiology.
[67] N. Leeper,et al. Thrombotic Regulation From the Endothelial Cell Perspectives. , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[68] A. Lebreton,et al. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis , 2018, Journal of thrombosis and haemostasis : JTH.
[69] D. Sacchi,et al. Pathology of idiopathic non-cirrhotic portal hypertension , 2018, Virchows Archiv.
[70] D. Bauer,et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity , 2018, Alimentary pharmacology & therapeutics.
[71] D. Valla. Budd–Chiari syndrome/hepatic venous outflow tract obstruction , 2018, Hepatology International.
[72] M. Merli,et al. Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[73] S. Caldwell,et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case‐control study , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[74] M. Moia,et al. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[75] D. Colomer,et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. , 2017, Journal of hepatology.
[76] T. Roskams,et al. Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[77] R. Porte,et al. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases , 2017, Research and practice in thrombosis and haemostasis.
[78] M. Avila,et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells , 2017, Hepatology.
[79] A. de Gottardi,et al. Antithrombotic treatment with direct‐acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[80] T. Deloughery,et al. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis , 2017, European journal of haematology.
[81] J. How,et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease , 2017, Therapeutic advances in hematology.
[82] F. Pomero,et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome , 2017, Thrombosis and Haemostasis.
[83] P. Mannucci,et al. Changing Concepts of Cirrhotic Coagulopathy , 2017, The American Journal of Gastroenterology.
[84] S. Basili,et al. Low‐grade endotoxemia and platelet activation in cirrhosis , 2017, Hepatology.
[85] S. Middeldorp. Inherited thrombophilia: a double-edged sword. , 2016, Hematology. American Society of Hematology. Education Program.
[86] V. Novakovic,et al. Phosphatidylserine on blood cells and endothelial cells contributes to the hypercoagulable state in cirrhosis , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[87] C. Colak,et al. Incidence and clinical presentation of portal vein thrombosis in cirrhotic patients. , 2016, Hepatobiliary & pancreatic diseases international : HBPD INT.
[88] L. Christou,et al. High von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosis , 2016, Hepatology.
[89] P. Kamath,et al. Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. , 2016, Gastroenterology.
[90] L. Santambrogio,et al. Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. , 2016, Blood.
[91] D. Valla,et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension , 2016, Hepatology.
[92] M. Pompili,et al. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study , 2016, Internal and Emergency Medicine.
[93] A. Farcomeni,et al. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry , 2016, Internal and Emergency Medicine.
[94] L. Giacomelli,et al. Obliterative portal venopathy without portal hypertension: an underestimated condition , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[95] M. Sakayori,et al. Trousseau's syndrome: cancer-associated thrombosis. , 2016, Japanese journal of clinical oncology.
[96] S. Caldwell,et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation , 2016, Digestive Diseases and Sciences.
[97] D. Fan,et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis , 2016, European journal of gastroenterology & hepatology.
[98] A. Tefferi,et al. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors , 2015, Blood Cancer Journal.
[99] S. Verma,et al. Endothelial cell control of thrombosis , 2015, BMC Cardiovascular Disorders.
[100] M. Hashizume,et al. Comprehensive Screening of Gene Function and Networks by DNA Microarray Analysis in Japanese Patients with Idiopathic Portal Hypertension , 2015, Mediators of inflammation.
[101] L. Pasta,et al. Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population. , 2015, Gene.
[102] A. Franco,et al. Platelets at the interface of thrombosis, inflammation, and cancer. , 2015, Blood.
[103] F. Leebeek,et al. The Fibrinolytic Status in Liver Diseases , 2015, Seminars in Thrombosis & Hemostasis.
[104] J. Verheij,et al. Idiopathic non-cirrhotic portal hypertension: a review , 2015, Orphanet Journal of Rare Diseases.
[105] A. Tawfik,et al. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system , 2015, European journal of gastroenterology & hepatology.
[106] R. Groszmann,et al. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. , 2015, Journal of hepatology.
[107] O. Christophe,et al. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. , 2015, Blood.
[108] D. Valla,et al. Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis , 2015, Haematologica.
[109] S. Chevret,et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study , 2015, Hepatology.
[110] Baljendra Kapoor,et al. Diagnosis and Management of Budd Chiari Syndrome: An Update , 2015, CardioVascular and Interventional Radiology.
[111] D. Fan,et al. Associations of Antiphospholipid Antibodies With Splanchnic Vein Thrombosis , 2015, Medicine.
[112] D. Schuppan,et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. , 2014, Gastroenterology.
[113] Jin-Wook Kim,et al. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis , 2014, Clinical and molecular hepatology.
[114] D. Fan,et al. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[115] R. Porte,et al. Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. , 2014, Thrombosis research.
[116] A. Berzigotti,et al. Idiopathic portal hypertension: Natural history and long‐term outcome , 2014, Hepatology.
[117] O. Riggio,et al. Idiopathic Non Cirrhotic Portal Hypertension and Spleno-Portal Axis Abnormalities in Patients with Severe Primary Antibody Deficiencies , 2014, Journal of immunology research.
[118] K. Peerlinck,et al. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII , 2014, Journal of thrombosis and haemostasis : JTH.
[119] C. Musumba. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy , 2013, Alimentary pharmacology & therapeutics.
[120] Q. Jiang,et al. Clinical and pathological features and surgical treatment of Budd‐Chiari syndrome‐associated hepatocellular carcinoma , 2013, Chinese medical journal.
[121] Víctor M. Navarro,et al. Common Variable Immunodeficiency Causing Non-cirrhotic Portal Hypertension: Case Report and a Review of Literature: 1188 , 2013 .
[122] V. Ertekin,et al. Hepatoportal Sclerosis in Childhood: Descriptive Analysis of 12 Patients , 2013, Journal of Korean medical science.
[123] P. Mannucci,et al. Global coagulation in myeloproliferative neoplasms , 2013, Annals of Hematology.
[124] D. Valla,et al. Behcet’s disease in budd-chiari syndrome , 2013, Orphanet Journal of Rare Diseases.
[125] M. De Grandis,et al. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. , 2013, Blood.
[126] D. Valla,et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. , 2012, Blood.
[127] M. Hashizume,et al. Prognostic factors in patients with idiopathic portal hypertension: Two Japanese nationwide epidemiological surveys in 1999 and 2005 , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.
[128] J. Schouten,et al. Risk factors and outcome of HIV‐associated idiopathic noncirrhotic portal hypertension , 2012, Alimentary pharmacology & therapeutics.
[129] Zhenpeng Qiu,et al. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin‐induced apoptosis by inhibiting p53 activation , 2012, Hepatology.
[130] D. Valla,et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. , 2012, Gastroenterology.
[131] A. Gasbarrini,et al. What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. , 2012, World journal of gastroenterology.
[132] P. Simioni,et al. Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis , 2012, Journal of thrombosis and haemostasis : JTH.
[133] J. García‐Pagán,et al. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. , 2012, Journal of hepatology.
[134] B. Şahın,et al. Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[135] T. Roskams,et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long‐term cohort study , 2012, Alimentary pharmacology & therapeutics.
[136] P. Mannucci,et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma , 2012, Internal and Emergency Medicine.
[137] Y. Iwakiri. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[138] V. Brancaccio,et al. Antiphospholipid Antibodies and Antiphospholipid Syndrome: Role in Portal Vein Thrombosis in Patients With and Without Liver Cirrhosis , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[139] T. Cenci,et al. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. , 2011, Blood.
[140] P. Vanhems,et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. , 2011, Journal of hepatology.
[141] F. Leebeek,et al. Hypercoagulability and Hypofibrinolysis and Risk of Deep Vein Thrombosis and Splanchnic Vein Thrombosis: Similarities and Differences , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[142] V. Paradis,et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. , 2011, Journal of hepatology.
[143] G. Gerken,et al. Low‐molecular‐weight heparin in patients with advanced cirrhosis , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[144] A. Bergquist,et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study , 2010, Alimentary pharmacology & therapeutics.
[145] Mercedes Fernandez,et al. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. , 2010, Journal of hepatology.
[146] P. Mannucci,et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method , 2010, Hepatology.
[147] S. Ahn,et al. [Deficiencies in proteins C and S in a patient with idiopathic portal hypertension accompanied by portal vein thrombosis]. , 2010, The Korean journal of hepatology.
[148] V. Soriano,et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings , 2010, AIDS.
[149] P. Mannucci,et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. , 2009, Gastroenterology.
[150] S. Chanock,et al. A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations , 2009, PloS one.
[151] A. Gasbarrini,et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. , 2009, Journal of hepatology.
[152] F. Rosendaal,et al. Etiology, management, and outcome of the Budd-Chiari syndrome. , 2009, Annals of internal medicine.
[153] T. Schiano,et al. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. , 2009, Blood.
[154] T. Barbui,et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. , 2008, Blood.
[155] S. Chevret,et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. , 2008, Blood.
[156] M. Gianni,et al. Inherited thrombophilic abnormalities and risk of portal vein thrombosis , 2008, Thrombosis and Haemostasis.
[157] Mercedes Fernandez,et al. Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability , 2007, Hepatology.
[158] G. Tiscia,et al. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. , 2007, Blood.
[159] R. Jalan,et al. The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece? , 2007, Hepatology.
[160] N. Enomoto,et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. , 2007, Journal of hepatology.
[161] M. Björck,et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. , 2006, World journal of gastroenterology.
[162] Toshio Mori,et al. Localization of ADAMTS13 to the stellate cells of human liver. , 2005, Blood.
[163] C. Yurdaydın,et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis , 2005, European journal of gastroenterology & hepatology.
[164] A. Tripodi,et al. LIVER FAILURE AND LIVER DISEASE , 2005 .
[165] N. Mackman. Role of tissue factor in hemostasis, thrombosis, and vascular development. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[166] Y. Okada,et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. , 2004, Biochemical and biophysical research communications.
[167] D. Valla,et al. Vascular involvement of the liver in Turner's syndrome , 2004, Hepatology.
[168] T. Hamamoto,et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? , 2001, Journal of biochemistry.
[169] L. Blendis,et al. Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension , 1995, Hepatology.
[170] M. Omata,et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. , 1988, Gastroenterology.
[171] S. Sarin,et al. Familial aggregation in noncirrhotic portal fibrosis: a report of four families. , 1987, The American journal of gastroenterology.
[172] K. Okuda,et al. Splanchnic hemodynamics in portal hypertensive dogs with portal fibrosis. , 1987, The American journal of physiology.
[173] A. Falanga,et al. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. , 1985, Biochemistry.
[174] D. Valla,et al. EASL Clinical Practice Guidelines: Vascular diseases of the liver. , 2016, Journal of hepatology.
[175] Akie Hirata,et al. Idiopathic portal hypertension in a patient with mixed connective tissue disease and protein C deficiency. , 2010, Internal medicine.
[176] D. Valla. Primary Budd-Chiari syndrome. , 2009, Journal of hepatology.
[177] H. Janssen,et al. Vascular liver disorders (II): portal vein thrombosis. , 2009, The Netherlands journal of medicine.
[178] N. Hassan,et al. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. , 2005, Pharmacological research.
[179] A. Bernardo,et al. Hemostasis, Thrombosis, and Vascular Biology , 2022 .
[180] K. Rák,et al. Endothelium releases more von Willebrand factor and tissue-type plasminogen activator upon venous occlusion in patients with liver cirrhosis than in normals. , 1993, Haemostasis.